Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

Novo Nordisk’s SOUL trial confirms that oral semaglutide significantly reduces the risk of heart attack, stroke, and ...

Trial confirms that oral semaglutide lowers cardiovascular risk in type 2 diabetes, regardless of SGLT2i use. Read more!

A new international clinical trial has shown that the oral form of semaglutide, a medication already known for managing type ...

in patients with T2Ds when given as an oral therapy. The results of the SOUL trial reveal that the Danish pharma's Rybelsus formulation of semaglutide reduced the risk of MACE (cardiovascular ...

Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney ...